We also provide evidence suggesting stark differences between the path to T cell dysfunction in ccRCC and that in other tumor types or in chronic infection at the level of TFs (for example, TBX5) and surface markers (for example, CD101). This evidence concerns the gene TBX5 and neoplasm.